CO7091177A2 - Inhibidores de la beta-secretasa - Google Patents
Inhibidores de la beta-secretasaInfo
- Publication number
- CO7091177A2 CO7091177A2 CO14215177A CO14215177A CO7091177A2 CO 7091177 A2 CO7091177 A2 CO 7091177A2 CO 14215177 A CO14215177 A CO 14215177A CO 14215177 A CO14215177 A CO 14215177A CO 7091177 A2 CO7091177 A2 CO 7091177A2
- Authority
- CO
- Colombia
- Prior art keywords
- beta
- secretase inhibitors
- secretase
- inhibitors
- see annexes
- Prior art date
Links
- 239000002439 beta secretase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/02—Thiocyanates
- C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
- C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606786P | 2012-03-05 | 2012-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7091177A2 true CO7091177A2 (es) | 2014-10-21 |
Family
ID=47902355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14215177A CO7091177A2 (es) | 2012-03-05 | 2014-09-29 | Inhibidores de la beta-secretasa |
Country Status (39)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2724886C (en) | 2008-05-23 | 2017-11-14 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
| KR20120001756A (ko) | 2009-03-13 | 2012-01-04 | 비타이 파마슈티컬즈, 인코포레이티드 | 베타세크리타아제 저해제 |
| EP2539322B1 (en) | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
| US9376409B2 (en) | 2012-05-09 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
| TW201422592A (zh) * | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β－分泌酶抑制劑 |
| WO2014052398A1 (en) | 2012-09-28 | 2014-04-03 | Vitae Pharmaceuticals, Inc. | Inhibitor of beta-secretase |
| WO2014081558A1 (en) | 2012-11-21 | 2014-05-30 | Boehringer Ingelheim International Gmbh | PROCESS FOR MAKING N-SULFINYL a-AMINO AMIDES |
| EP3194439B1 (en) | 2014-09-19 | 2022-01-19 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| AR102202A1 (es) | 2014-10-07 | 2017-02-08 | Astrazeneca Ab | Compuestos de oxazol y su uso como inhibidores de bace de oxazol |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| EP3337829B1 (en) | 2016-02-19 | 2020-01-08 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
| KR20180133452A (ko) * | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
| WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US11077108B2 (en) * | 2016-09-07 | 2021-08-03 | The Regents Of The University Of California | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition |
| US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| EP3946606B1 (en) | 2019-03-27 | 2025-01-01 | Insilico Medicine IP Limited | Bicyclic jak inhibitors and uses thereof |
| US12297244B2 (en) | 2019-06-05 | 2025-05-13 | Rensselaer Polytechnic Institute | Systems and methods for inhibiting γ-secretase production of amyloid-β peptides |
| BE1027699B1 (fr) * | 2021-01-28 | 2022-04-01 | Trasis S A | Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués |
| CN113082209A (zh) * | 2021-03-31 | 2021-07-09 | 中国科学技术大学 | Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5745185A (en) | 1980-07-21 | 1982-03-13 | Eisai Co Ltd | Hydantoin derivative and its preparation |
| WO1993005045A1 (en) | 1991-08-28 | 1993-03-18 | The Upjohn Company | Spirocyclic benzopyran imidazolines |
| CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
| EP2153832B1 (en) | 2003-12-15 | 2016-03-09 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| PE20060459A1 (es) | 2004-06-16 | 2006-05-30 | Wyeth Corp | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA |
| EP1758907B1 (en) | 2004-06-16 | 2009-02-18 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
| EP1804794B1 (en) | 2004-10-13 | 2013-07-31 | Merck Sharp & Dohme Corp. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease |
| ATE482214T1 (de) | 2005-06-14 | 2010-10-15 | Schering Corp | Aspartylproteasehemmer |
| MX2007016182A (es) | 2005-06-14 | 2008-03-07 | Schering Corp | Inhibidores de aspartil proteasas. |
| JP2009500329A (ja) | 2005-06-30 | 2009-01-08 | ワイス | アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用 |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| RU2423568C2 (ru) | 2005-07-29 | 2011-07-10 | Конинклейке Филипс Электроникс Н.В. | Устройство для глажения с паром |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| JP2009509957A (ja) | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物 |
| EP2612854B1 (en) | 2005-10-25 | 2015-04-29 | Shionogi&Co., Ltd. | Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| DE102005057688A1 (de) | 2005-12-01 | 2007-06-14 | Endress + Hauser Flowtec Ag | Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums |
| EP1966185A2 (en) | 2005-12-19 | 2008-09-10 | Wyeth a Corporation of the State of Delaware | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION |
| WO2007076284A2 (en) | 2005-12-20 | 2007-07-05 | Fieldbus Foundation | System and method for implementing safety instrumented systems |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| EP2644600B1 (en) | 2006-06-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| PT2042480E (pt) | 2006-07-18 | 2013-06-24 | Astellas Pharma Inc | Derivado de aminoindano ou um seu sal |
| WO2008030412A2 (en) | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| WO2008076043A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5,5-diaryl-imidazol-4-ones |
| TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| PE20090160A1 (es) | 2007-03-20 | 2009-02-11 | Wyeth Corp | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA |
| PE20090617A1 (es) | 2007-03-23 | 2009-05-08 | Wyeth Corp | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| JP5383484B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | 環式基で置換されたアミノジヒドロチアジン誘導体 |
| TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| EP2077637B1 (en) | 2007-12-12 | 2020-03-11 | Alcatel Lucent | System and method for protecting payload information in radio transmission |
| CN101952260B (zh) | 2008-02-18 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-*唑-2-基胺衍生物 |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| EP2324032B1 (en) | 2008-08-19 | 2014-10-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| JP5579720B2 (ja) | 2008-09-11 | 2014-08-27 | アムジエン・インコーポレーテツド | ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法 |
| GEP20135806B (en) * | 2008-11-23 | 2013-04-10 | Pfizer | Lactams as beta secretase inhibitors |
| KR20120001756A (ko) * | 2009-03-13 | 2012-01-04 | 비타이 파마슈티컬즈, 인코포레이티드 | 베타세크리타아제 저해제 |
| WO2011072064A1 (en) | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors |
| EP2539322B1 (en) * | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| US20120065195A1 (en) | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
-
2013
- 2013-02-06 TW TW102104519A patent/TWI557112B/zh not_active IP Right Cessation
- 2013-03-04 ME MEP-2016-74A patent/ME02390B/me unknown
- 2013-03-04 HR HRP20160415TT patent/HRP20160415T1/hr unknown
- 2013-03-04 AP AP2014007900A patent/AP4029A/en active
- 2013-03-04 EP EP13710937.7A patent/EP2822930B1/en active Active
- 2013-03-04 SG SG11201404600VA patent/SG11201404600VA/en unknown
- 2013-03-04 MY MYPI2014002293A patent/MY171091A/en unknown
- 2013-03-04 WO PCT/US2013/028796 patent/WO2013134085A1/en not_active Ceased
- 2013-03-04 JP JP2014560985A patent/JP6161643B2/ja not_active Expired - Fee Related
- 2013-03-04 UA UAA201410695A patent/UA113641C2/uk unknown
- 2013-03-04 RS RS20160246A patent/RS54730B1/sr unknown
- 2013-03-04 NZ NZ629239A patent/NZ629239A/en not_active IP Right Cessation
- 2013-03-04 EA EA201491534A patent/EA024995B1/ru not_active IP Right Cessation
- 2013-03-04 IN IN6710DEN2014 patent/IN2014DN06710A/en unknown
- 2013-03-04 CN CN201380012529.9A patent/CN104271558B/zh not_active Expired - Fee Related
- 2013-03-04 PE PE2014001347A patent/PE20141972A1/es active IP Right Grant
- 2013-03-04 SI SI201330173A patent/SI2822930T1/sl unknown
- 2013-03-04 MX MX2014010625A patent/MX353432B/es active IP Right Grant
- 2013-03-04 KR KR1020147026838A patent/KR20140138774A/ko not_active Ceased
- 2013-03-04 BR BR112014021269A patent/BR112014021269A2/pt active Search and Examination
- 2013-03-04 US US13/784,032 patent/US8981112B2/en active Active
- 2013-03-04 AU AU2013230523A patent/AU2013230523B2/en not_active Ceased
- 2013-03-04 DK DK13710937.7T patent/DK2822930T3/en active
- 2013-03-04 CA CA2864143A patent/CA2864143C/en not_active Expired - Fee Related
- 2013-03-04 UY UY0001034654A patent/UY34654A/es active IP Right Grant
- 2013-03-04 HU HUE13710937A patent/HUE027289T2/en unknown
- 2013-03-04 ES ES13710937.7T patent/ES2568928T3/es active Active
- 2013-03-04 PL PL13710937.7T patent/PL2822930T3/pl unknown
- 2013-03-05 AR ARP130100706A patent/AR090241A1/es active IP Right Grant
-
2014
- 2014-07-30 IL IL233887A patent/IL233887A/en active IP Right Grant
- 2014-07-31 TN TNP2014000326A patent/TN2014000326A1/fr unknown
- 2014-08-08 ZA ZA2014/05846A patent/ZA201405846B/en unknown
- 2014-09-02 PH PH12014501963A patent/PH12014501963A1/en unknown
- 2014-09-02 CL CL2014002334A patent/CL2014002334A1/es unknown
- 2014-09-26 MA MA37375A patent/MA35945B1/fr unknown
- 2014-09-29 EC ECIEPI201420640A patent/ECSP14020640A/es unknown
- 2014-09-29 CO CO14215177A patent/CO7091177A2/es unknown
-
2015
- 2015-02-04 US US14/613,550 patent/US9526727B2/en not_active Expired - Fee Related
-
2016
- 2016-04-19 SM SM201600114T patent/SMT201600114B/it unknown
- 2016-04-19 CY CY20161100327T patent/CY1117543T1/el unknown
- 2016-12-19 US US15/383,287 patent/US9949975B2/en active Active
-
2017
- 2017-10-02 AU AU2017236042A patent/AU2017236042B2/en not_active Ceased
-
2018
- 2018-03-12 US US15/918,546 patent/US20180344734A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7091177A2 (es) | Inhibidores de la beta-secretasa | |
| CO7111289A2 (es) | Compuestos inhibidores de metaloenzimas | |
| CO7020912A2 (es) | Inhibidores de bromodominios | |
| UY34836A (es) | Nuevo organismos | |
| UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| CO7350623A2 (es) | Agentes moduladores de autotaxina (atx) | |
| UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
| EP2928898A4 (en) | BETA-Lactamase INHIBITORS | |
| CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
| BR112013010099A2 (pt) | boronatos como inibidores de arginase | |
| UY33930A (es) | Inhibidores novedosos de quinasas | |
| EP2920168A4 (en) | Heterocyclic glutaminease inhibitors | |
| BR112015003294A2 (pt) | caldeira de armazenamento | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| CO7151512A2 (es) | Inhibidores del nampt | |
| BR112014003027A2 (pt) | formulação herbicida melhorada | |
| CO7151499A2 (es) | Formulación inyectable | |
| CO7020915A2 (es) | Inhibidores de iap | |
| BR112014026634A2 (pt) | direcionador | |
| UY34158A (es) | Composicion herbicida | |
| PT2834233T (pt) | Novos agonistas de adrenoceptores alfa2 | |
| UY4181Q (es) | Taza | |
| BR112014027219A2 (pt) | método | |
| EP2858975A4 (en) | FBXO3 INHIBITORS |